VX-121 Combination Therapy in Subjects With Cystic Fibrosis VX20-121-103
Diseases of the Endocrine System | Genetics - Adult | Genetics - Pediatric
What is the purpose of this trial?
The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del and a gating (F/G) or residual function (F/RF) mutation, or have at least 1 other TCR CF transmembrane conductance regulator (CFTR) gene mutation and no F508del mutation.
- Ages12 years and older
- Trial withVertex Pharmaceuticals Incorporated
- Start Date12/16/2021
- End Date07/31/2023
- Last Updated05/09/2022
- Study HIC#2000030926